登革热、COVID-19（SARS-CoV-2）和抗体依赖性增强（ADE）：一个视角。
Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.
机构信息
Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Department of Microbiology and Parasitology, Health Sciences Center, Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil.
出版信息
Cytometry A. 2020 Jul;97(7):662-667. doi: 10.1002/cyto.a.24047. Epub 2020 Jun 7.
Abstract
SARS-CoV-2 pandemic and recurrent dengue epidemics in tropical countries have turned into a global health threat. While both virus-caused infections may only reveal light symptoms, they can also cause severe diseases. Here, we review the possible antibody-dependent enhancement (ADE) occurrence, known for dengue infections, when there is a second infection with a different virus strain. Consequently, preexisting antibodies do not neutralize infection, but enhance it, possibly by triggering Fcγ receptor-mediated virus uptake. No clinical data exist indicating such mechanism for SARS-CoV-2, but previous coronavirus infections or infection of SARS-CoV-2 convalescent with different SARS-CoV-2 strains could promote ADE, as experimentally shown for antibodies against the MERS-CoV or SARS-CoV spike S protein. © 2020 International Society for Advancement of Cytometry.
摘要
SARS-CoV-2 大流行和热带国家反复发生的登革热疫情已成为全球健康威胁。虽然这两种病毒引起的感染可能仅表现出轻微症状，但也可能导致严重疾病。在这里，我们回顾了已知可能发生的抗体依赖性增强（ADE），即当第二次感染不同病毒株时，登革热感染会发生这种情况。因此，预先存在的抗体不能中和感染，反而会增强感染，可能通过触发 Fcγ 受体介导的病毒摄取。目前尚无临床数据表明 SARS-CoV-2 存在这种机制，但以前的冠状病毒感染或 SARS-CoV-2 恢复期感染不同的 SARS-CoV-2 株可能会促进 ADE，正如实验中针对 MERS-CoV 或 SARS-CoV 刺突 S 蛋白的抗体所示。© 2020 国际细胞分析学会。
相似文献
1
Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.登革热、COVID-19（SARS-CoV-2）和抗体依赖性增强（ADE）：一个视角。
Cytometry A. 2020 Jul;97(7):662-667. doi: 10.1002/cyto.a.24047. Epub 2020 Jun 7.
2
A perspective on potential antibody-dependent enhancement of SARS-CoV-2.对 SARS-CoV-2 潜在抗体依赖性增强作用的看法。
Nature. 2020 Aug;584(7821):353-363. doi: 10.1038/s41586-020-2538-8. Epub 2020 Jul 13.
3
Antibody-dependent enhancement of coronavirus.抗体依赖性增强冠状病毒感染。
Int J Infect Dis. 2020 Nov;100:483-489. doi: 10.1016/j.ijid.2020.09.015. Epub 2020 Sep 11.
4
The role of IgG Fc receptors in antibody-dependent enhancement.IgG Fc 受体在抗体依赖的增强中的作用。
Nat Rev Immunol. 2020 Oct;20(10):633-643. doi: 10.1038/s41577-020-00410-0. Epub 2020 Aug 11.
5
Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.由于原始抗原性失误和 SARS 的发展而导致的抗体依赖性增强。
Front Immunol. 2020 Jun 5;11:1120. doi: 10.3389/fimmu.2020.01120. eCollection 2020.
6
The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections.SARS-CoV、MERS-CoV 和 SARS-CoV-2 冠状病毒感染的比较免疫学特征。
Front Immunol. 2020 Aug 14;11:2033. doi: 10.3389/fimmu.2020.02033. eCollection 2020.
7
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.2020 年大流行：当前 SARS-CoV-2 疫苗的开发。
Front Immunol. 2020 Aug 19;11:1880. doi: 10.3389/fimmu.2020.01880. eCollection 2020.
8
S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.人类感染 SARS-CoV-2 后 S 蛋白反应性 IgG 和记忆 B 细胞的产生包括对 S2 亚基的广泛反应性。
mBio. 2020 Sep 25;11(5):e01991-20. doi: 10.1128/mBio.01991-20.
9
Covid-19 and dengue: Double punches for dengue-endemic countries in Asia.Covid-19 和登革热：亚洲登革热流行国家的双重打击。
Rev Med Virol. 2021 Mar;31(2):e2161. doi: 10.1002/rmv.2161. Epub 2020 Sep 18.
10
Antibody-dependent enhancement (ADE) of SARS-CoV-2 in patients exposed to MERS-CoV and SARS-CoV-2 antigens.抗体依赖增强作用（ADE）在接触 MERS-CoV 和 SARS-CoV-2 抗原的患者中对 SARS-CoV-2 的影响。
J Med Virol. 2024 May;96(5):e29628. doi: 10.1002/jmv.29628.
引用本文的文献
1
Identification of Rhododendron mariae extraction as a new attachment inhibitor against dengue virus by targeting the envelope protein domain III.通过靶向包膜蛋白结构域III鉴定杜鹃提取物作为一种新型登革病毒附着抑制剂
Front Immunol. 2025 Aug 13;16:1663878. doi: 10.3389/fimmu.2025.1663878. eCollection 2025.
2
Vector-borne diseases and their role in COVID-19 dynamics and death rates: focus on India.媒介传播疾病及其在新冠疫情动态和死亡率中的作用：以印度为重点。
Folia Microbiol (Praha). 2025 Aug 9. doi: 10.1007/s12223-025-01313-0.
3
Recent advances in the control of dengue fever using herbal and synthetic drugs.使用草药和合成药物控制登革热的最新进展。
Heliyon. 2025 Jan 18;11(3):e41939. doi: 10.1016/j.heliyon.2025.e41939. eCollection 2025 Feb 15.
4
Antibody-dependent enhancement of coronaviruses.冠状病毒的抗体依赖性增强作用。
Int J Biol Sci. 2025 Feb 3;21(4):1686-1704. doi: 10.7150/ijbs.96112. eCollection 2025.
5
The Ambivalence of Post COVID-19 Vaccination Responses in Humans.人类对 COVID-19 疫苗接种反应的矛盾心理。
Biomolecules. 2024 Oct 17;14(10):1320. doi: 10.3390/biom14101320.
6
Dengue Fever Accompanied by Neurological Manifestations: Challenges and Treatment.登革热伴发神经症状：挑战与治疗
Cureus. 2024 May 23;16(5):e60961. doi: 10.7759/cureus.60961. eCollection 2024 May.
7
Strategies of rational and structure-driven vaccine design for Arenaviruses.理性和结构驱动的沙粒病毒疫苗设计策略。
Infect Genet Evol. 2024 Sep;123:105626. doi: 10.1016/j.meegid.2024.105626. Epub 2024 Jun 20.
8
Oro-Pharyngeal Candidiasis in Two Dengue Patients.两名登革热患者的口咽念珠菌病
Cureus. 2024 Jan 20;16(1):e52627. doi: 10.7759/cureus.52627. eCollection 2024 Jan.
9
Neurological Complications in Dengue Among Males of the Adult Age Group.成年男性登革热患者的神经系统并发症
Cureus. 2024 Jan 3;16(1):e51586. doi: 10.7759/cureus.51586. eCollection 2024 Jan.
10
Optimizing SARS-CoV-2 Immunoassays for Specificity in Dengue-Co-Endemic Areas.优化严重急性呼吸综合征冠状病毒2免疫测定法以提高登革热共同流行地区的特异性
Cureus. 2023 Oct 25;15(10):e47683. doi: 10.7759/cureus.47683. eCollection 2023 Oct.
本文引用的文献
1
No evidence for distinct types in the evolution of SARS-CoV-2.没有证据表明新冠病毒（SARS-CoV-2）在进化过程中存在不同类型。
Virus Evol. 2020 May 14;6(1):veaa034. doi: 10.1093/ve/veaa034. eCollection 2020 Jan.
2
SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses.SARS-CoV-2 蛋白组微阵列用于全面分析 COVID-19 特异性 IgG 和 IgM 反应。
Nat Commun. 2020 Jul 14;11(1):3581. doi: 10.1038/s41467-020-17488-8.
3
Virus strain from a mild COVID-19 patient in Hangzhou represents a new trend in SARS-CoV-2 evolution potentially related to Furin cleavage site.从杭州轻症 COVID-19 患者中分离出的病毒株代表了 SARS-CoV-2 进化的新趋势，可能与弗林蛋白酶裂解位点有关。
Emerg Microbes Infect. 2020 Dec;9(1):1474-1488. doi: 10.1080/22221751.2020.1781551.
4
Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other Infectious Agents.基于流式细胞术的未固定严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染细胞和其他传染性病原体的分选程序。
Cytometry A. 2020 Jul;97(7):674-680. doi: 10.1002/cyto.a.24040. Epub 2020 Jun 3.
5
Human neutralizing antibodies elicited by SARS-CoV-2 infection.SARS-CoV-2 感染诱导的人体中和抗体。
Nature. 2020 Aug;584(7819):115-119. doi: 10.1038/s41586-020-2380-z. Epub 2020 May 26.
6
Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.免疫增强对新冠病毒多克隆高免球蛋白治疗和疫苗开发的影响。
EBioMedicine. 2020 May;55:102768. doi: 10.1016/j.ebiom.2020.102768. Epub 2020 Apr 16.
7
The potential danger of suboptimal antibody responses in COVID-19.新冠肺炎中抗体反应欠佳的潜在危险。
Nat Rev Immunol. 2020 Jun;20(6):339-341. doi: 10.1038/s41577-020-0321-6.
8
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.CD147 作为 COVID-19 治疗靶点：阿奇霉素和干细胞干预的建议作用。
Stem Cell Rev Rep. 2020 Jun;16(3):434-440. doi: 10.1007/s12015-020-09976-7.
9
Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses.冠状病毒感染：流行病学、临床及免疫学特征与假说
Cell Stress. 2020 Mar 2;4(4):66-75. doi: 10.15698/cst2020.04.216.
10
Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm.处理和检测 COVID-19 患者的血液样本，以安全地研究细胞表型和细胞因子风暴。
Cytometry A. 2020 Jul;97(7):668-673. doi: 10.1002/cyto.a.24009. Epub 2020 Apr 10.
Zotero 插件